Search

Your search keyword '"Ladon, Dariusz"' showing total 16 results
Start Over Author "Ladon, Dariusz" Search Limiters Available in Library Collection
16 results on '"Ladon, Dariusz"'

1. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Author

Shah, Mithun Vinod, Tran, Elizabeth Ngoc Hoa, Shah, Syed, Chhetri, Rakchha, Baranwal, Anmol, Ladon, Dariusz, Shultz, Carl, Al-Kali, Aref, Brown, Anna L., Chen, Dong, Scott, Hamish S., Greipp, Patricia, Thomas, Daniel, Alkhateeb, Hassan B., Singhal, Deepak, Gangat, Naseema, Kumar, Sharad, Patnaik, Mrinal M., Hahn, Christopher N., Kok, Chung Hoow, Tefferi, Ayalew, and Hiwase, Devendra K.

Published
2023
Full Text
View/download PDF

2. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program

Author

Rice, Siobhan, Jackson, Thomas, Crump, Nicholas T., Fordham, Nicholas, Elliott, Natalina, O’Byrne, Sorcha, Fanego, Maria del Mar Lara, Addy, Dilys, Crabb, Trisevgeni, Dryden, Carryl, Inglott, Sarah, Ladon, Dariusz, Wright, Gary, Bartram, Jack, Ancliff, Philip, Mead, Adam J., Halsey, Christina, Roberts, Irene, Milne, Thomas A., and Roy, Anindita

Published
2021
Full Text
View/download PDF

3. Unraveling facets of MECOM-associated syndrome: somatic genetic rescue, clonal hematopoiesis, and phenotype expansion

Author

Venugopal, Parvathy, Arts, Peer, Fox, Lucy C., Simons, Annet, Hiwase, Devendra K., Bardy, Peter G., Swift, Annette, Ross, David M., van Vulpen, Lize F. D., Buijs, Arjan, Bolton, Kelly L., Getta, Bartlomiej, Furlong, Eliska, Carter, Tina, Krapels, Ingrid, Hoeks, Marlijn, Al Kindy, Adila, Al Kindy, Farah, de Munnik, Sonja, Evans, Pamela, Frank, Mahalia S. B., Bournazos, Adam M., Cooper, Sandra T., Ha, Thuong Thi, Jackson, Matilda R., Arriola-Martinez, Luis, Phillips, Kerry, Brennan, Yvonne, Bakshi, Madhura, Ambler, Karen, Gao, Song, Kassahn, Karin S., Kenyon, Rosalie, Hung, Kevin, Babic, Milena, McGovern, Alan, Rawlings, Lesley, Vakulin, Cassandra, Dejong, Lucas, Fathi, Rema, McRae, Simon, Myles, Nicholas, Ladon, Dariusz, Jongmans, Marjolijn, Kuiper, Roland P., Poplawski, Nicola K., Barbaro, Pasquale, Blombery, Piers, Brown, Anna L., Hahn, Christopher N., and Scott, Hamish S.

Published
2024
Full Text
View/download PDF

5. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Hiwase, Devendra K., primary, Hahn, Christopher N, additional, Tran, Elizabeth Ngoc Hoa, additional, Chhetri, Rakchha, additional, Baranwal, Anmol, additional, Al-Kali, Aref, additional, Sharplin, Kirsty M, additional, Ladon, Dariusz, additional, Hollins, Rachel, additional, Greipp, Patricia T., additional, Kutyna, Monika M., additional, Alkhateeb, Hassan B, additional, Badar, Talha, additional, Wang, Paul Po-Shen, additional, Ross, David M, additional, Singhal, Deepak, additional, Shanmuganathan, Naranie, additional, Bardy, Peter G, additional, Beligaswatte, Ashanka, additional, Yeung, David T, additional, Litzow, Mark R, additional, Mangaonkar, Abhishek A., additional, Giri, Pratyush, additional, Lee, Cindy H, additional, Yong, Angelina, additional, Horvath, Noemi, additional, Singhal, Nimit, additional, Gowda, Raghu, additional, Hogan, William J, additional, Gangat, Naseema, additional, Patnaik, Mrinal M., additional, Begna, Kebede, additional, Tiong, Ing Soo, additional, Wei, Andrew H, additional, Kumar, Sharad, additional, Brown, Anna L, additional, Scott, Hamish S, additional, Thomas, Daniel, additional, Kok, Chung Hoow, additional, Tefferi, Ayalew, additional, and Shah, Mithun Vinod, additional

Published
2022
Full Text
View/download PDF

6. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Author

Shah, Mithun V., primary, Hahn, Christopher N, additional, Tran, Elizabeth Ngoc Hoa, additional, Sharplin, Kirsty M, additional, Chhetri, Rakchha, additional, Baranwal, Anmol, additional, Kutyna, Monika M, additional, Wang, Paul, additional, Ladon, Dariusz, additional, Al-Kali, Aref, additional, Alkhateeb, Hassan B., additional, Ross, David M, additional, Yeung, David T, additional, Shanmuganathan, Naranie, additional, Litzow, Mark R., additional, Mangaonkar, Abhishek A., additional, Hogan, William J., additional, Gangat, Naseema, additional, Patnaik, Mrinal M.M., additional, Kebede, Begna, additional, Kumar, Sharad, additional, Singhal, Deepak, additional, Brown, Anna L., additional, Scott, Hamish S, additional, Thomas, Daniel, additional, Kok, Chung Hoow, additional, Tefferi, Ayalew, additional, and Hiwase, Devendra, additional

Published
2022
Full Text
View/download PDF

7. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Author

Kok, Chung Hoow, primary, Tran, Elizabeth Ngoc Hoa, additional, Ladon, Dariusz, additional, Chhetri, Rakchha, additional, Baranwal, Anmol, additional, Sharplin, Kirsty M, additional, Alkhateeb, Hassan B., additional, Singhal, Deepak, additional, Al-Kali, Aref, additional, Gangat, Naseema, additional, Yeung, David T, additional, Litzow, Mark R., additional, Ross, David M, additional, Hogan, William J., additional, Kebede, Ashanka Begna, additional, Mangaonkar, Abhishek A., additional, Patnaik, Mrinal M., additional, Tefferi, Ayalew, additional, Shanmuganathan, Naranie, additional, Kumar, Sharad, additional, Thomas, Daniel, additional, Shah, Mithun V., additional, and Hiwase, Devendra, additional

Published
2022
Full Text
View/download PDF

8. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Hiwase, Devendra, Hahn, Christopher, Tran, Elizabeth Ngoc Hoa, Chhetri, Rakchha, Baranwal, Anmol, Al-Kali, Aref, Sharplin, Kirsty, Ladon, Dariusz, Hollins, Rachel, Greipp, Patricia, Kutyna, Monika, Alkhateeb, Hassan, Badar, Talha, Wang, Paul, Ross, David M., Singhal, Deepak, Shanmuganathan, Naranie, Bardy, Peter, Beligaswatte, Ashanka, Yeung, David, Litzow, Mark R., Mangaonkar, Abhishek, Giri, Pratyush, Lee, Cindy, Yong, Angie, Horvath, Noemi, Singhal, Nimit, Gowda, Raghu, Hogan, William, Gangat, Naseema, Patnaik, Mrinal, Begna, Kebede, Tiong, Ing S., Wei, Andrew, Kumar, Sharad, Brown, Anna, Scott, Hamish, Thomas, Daniel, Kok, Chung H., Tefferi, Ayalew, and Shah, Mithun Vinod

Published
2023
Full Text
View/download PDF

9. TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL

Author

Ottaviano, Giorgio, primary, Georgiadis, Christos, additional, Syed, Farhatullah, additional, Gkazi, Soragia Athina, additional, Zhan, Hong, additional, Etuk, Annie, additional, Chu, Jan, additional, Pinner, Danielle, additional, Inglott, Sarah, additional, Gilmour, Kimberly, additional, Adams, Stuart, additional, Kricke, Susanne, additional, Izotova, Natalia, additional, Ladon, Dariusz, additional, Kubat, Agnieszka, additional, Veys, Paul, additional, Vora, Ajay, additional, Rao, Kanchan, additional, and Qasim, Waseem, additional

Published
2021
Full Text
View/download PDF

10. TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Author

Hiwase, Devendra, Hahn, Christopher, Tran, Elizabeth Ngoc Hoa, Chhetri, Rakchha, Baranwal, Anmol, Al-Kali, Aref, Sharplin, Kirsty, Ladon, Dariusz, Hollins, Rachel, Greipp, Patricia, Kutyna, Monika, Alkhateeb, Hassan, Badar, Talha, Wang, Paul, Ross, David M., Singhal, Deepak, Shanmuganathan, Naranie, Bardy, Peter, Beligaswatte, Ashanka, Yeung, David, Litzow, Mark R., Mangaonkar, Abhishek, Giri, Pratyush, Lee, Cindy, Yong, Angie, Horvath, Noemi, Singhal, Nimit, Gowda, Raghu, Hogan, William, Gangat, Naseema, Patnaik, Mrinal, Begna, Kebede, Tiong, Ing S., Wei, Andrew, Kumar, Sharad, Brown, Anna, Scott, Hamish, Thomas, Daniel, Kok, Chung H., Tefferi, Ayalew, and Shah, Mithun Vinod

Abstract

[Display omitted]

Published
2023
Full Text
View/download PDF

11. Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects

Author

Georgiadis, Christos, primary, Preece, Roland, additional, Nickolay, Lauren, additional, Etuk, Aniekan, additional, Petrova, Anastasia, additional, Ladon, Dariusz, additional, Danyi, Alexandra, additional, Humphryes-Kirilov, Neil, additional, Ajetunmobi, Ayokunmi, additional, Kim, Daesik, additional, Kim, Jin-Soo, additional, and Qasim, Waseem, additional

Published
2018
Full Text
View/download PDF

12. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

Author

Ross, Fiona M, Avet-Loiseau, Hervé, Ameye, Geneviève, Gutiérrez, Norma C, Liebisch, Peter, O'Connor, Sheila, Dalva, Klara, Fabris, Sonia, Testi, Adele M, Jarosova, Marie, Hodkinson, Clare, Collin, Anna, Kerndrup, Gitte, Kuglik, Petr, Ladon, Dariusz, Bernasconi, Paolo, Maes, Brigitte, Zemanova, Zuzana, Michalova, Kyra, Michaux, Lucienne, Neben, Kai, Hermansen, N Emil U, Rack, Katrina, Rocci, Alberto, Protheroe, Rebecca, Chiecchio, Laura, Poirel, Hélène, Sonneveld, Pieter, Nyegaard, Mette, Johnsen, Hans E, the European Myeloma Network, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Centre de génétique médicale UCL, UCL - (SLuc) Service d'hématologie, and Hematology

Subjects
medicine.medical_specialty, MEDLINE, Bioinformatics, 03 medical and health sciences, Prospective analysis, 0302 clinical medicine, Clinical report, Internal medicine, medicine, Humans, In Situ Hybridization, Fluorescence, Multiple myeloma, 030304 developmental biology, 0303 health sciences, Hematology, medicine.diagnostic_test, business.industry, Network on, medicine.disease, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, %22">Fish , Original Articles and Brief Reports, Multiple Myeloma, business, Fluorescence in situ hybridization
Abstract

The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analysed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise there was acceptable agreement on more than 1000 tests. The conclusions from the collaboration were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) Material should be part of the first draw of the aspirate; 2) Samples should be sent at suitable times that allow for the lengthy processing; 3) Most importantly PCs must be purified or specifically identified; 4) Positive cut-off levels should be the relatively conservative, 10% for fusion or break-apart probes and 20% for numerical abnormalities; 5) Informative probes should be combined to best effect; 6) In specialist laboratories a single experienced analyst is considered adequate; 7) At least 100 PC should be scored; 8) Essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) Suitable commercial probes are available for clinically relevant abnormalities; 10) The clinical report should be expressed clearly and must state the percentage of PC involved and method used for identification; 11) A retrospective European based FISH data bank linked to clinical data should be generated and 12) Prospective analysis should be centralized for upcoming trials based on the recommendations. EMN aims to build on these recommendations to establish standards for a common European database to define subgroups with prognostic significance. ispartof: Haematologica vol:97 issue:8 pages:1272-1277 ispartof: location:Italy status: published

Published
2012

13. Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort

Author

Shah, Mithun V, Kutyna, Monika, Shah, Syed, Tran, Elizabeth Ngoc Hoa, Baranwal, Anmol, Ladon, Dariusz, Al-Kali, Aref, Brown, Anna, Chen, Dong, Greipp, Patricia, Begna, Kebede, Litzow, Mark R., Hogan, William J., Bardy, Peter, Kumar, Sharad, Yeung, David T, Patnaik, Mrinal M., Foran, James M., He, Rong, Gangat, Naseema, Scott, Hamish S, Arana Yi, Cecilia Y., Alkhateeb, Hassan, Mangaonkar, Abhishek A, Thomas, Daniel, Hahn, Christopher Norman, Orazi, Attilio, Arber, Daniel A., Kok, Chung Hoow, Tefferi, Ayalew, and Hiwase, Devendra

Abstract

BACKGROUND:Recently proposed World Health Organization (WHO, 5 thedition) and International Consensus Classification (ICC) recognized myeloid neoplasms (MN) harboring TP53-mutated ( TP53mut) as a separate entity. However, there are critical differences between the two classifications regarding allelic-status, variance allele frequency (VAF) cut-off and blast categories, that may lead to under- or overestimation of the risk.

Published
2023
Full Text
View/download PDF

14. TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Author

Shah, Mithun V., Hahn, Christopher N, Tran, Elizabeth Ngoc Hoa, Sharplin, Kirsty M, Chhetri, Rakchha, Baranwal, Anmol, Kutyna, Monika M, Wang, Paul, Ladon, Dariusz, Al-Kali, Aref, Alkhateeb, Hassan B., Ross, David M, Yeung, David T, Shanmuganathan, Naranie, Litzow, Mark R., Mangaonkar, Abhishek A., Hogan, William J., Gangat, Naseema, Patnaik, Mrinal M.M., Kebede, Begna, Kumar, Sharad, Singhal, Deepak, Brown, Anna L., Scott, Hamish S, Thomas, Daniel, Kok, Chung Hoow, Tefferi, Ayalew, and Hiwase, Devendra

Published
2022
Full Text
View/download PDF

16. Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.

Author

Wechalekar MD, Zhao LP, Kutyna MM, Hong LE, Li J, Hung K, Scott HS, Brown A, Hahn CC, Kassahn K, Ladon D, Yeung DT, Thomas D, Patnaik M, Proudman S, Ades L, Shah MV, Kok CH, and Hiwase DK

Subjects
Humans, Female, Male, Middle Aged, Aged, Rheumatic Diseases drug therapy, Adult, Antirheumatic Agents therapeutic use, Antirheumatic Agents adverse effects, Methotrexate therapeutic use, Methotrexate adverse effects, Autoimmune Diseases drug therapy, Autoimmune Diseases chemically induced
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results